pituitary axis is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-08-31. Numbers and descriptions here follow the published literature rather than marketing material.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C221H366N72O67S | Reflects a 44-residue peptide with one N-terminal modification |
| Approximate molecular weight | 5136 Da | Sequence length and single acyl group determine the mass |
| Appearance | White to off-white lyophilized powder | Typical form of a purified synthetic peptide |
| Solubility class | Soluble in water and aqueous buffer | Peptide backbone favors aqueous dissolution |
| Common synonyms | GHRH(1-44) analogue; Egrifta | Descriptive name and approved brand name |
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
=== EC 2.7.8: Transferases for other substituted phosphate groups === EC 2.7.8.1: diacylglycerol ethanolaminephosphotransferase EC 2.7.8.2: diacylglycerol cholinephosphotransferase EC 2.7.8.3: ceramide cholinephosphotransferase EC 2.7.8.4: serine ethanolaminephosphotransferase EC 2.7.8.5: CDP-diacylglycerol—glycerol-3-phosphate 1-phosphatidyltransferase EC 2.7.8.6: undecaprenyl-phosphate galactose phosphotransferase EC 2.7.8.7: holo-[acyl-carrier-protein] synthase EC 2.7.8.8: CDP-diacylglycerol—serine O-phosphatidyltransferase EC 2.7.8.9: phosphomannan mannosephosphotransferase EC 2.7.8.10: sphingosine cholinephosphotransferase EC 2.7.8.11: CDP-diacylglycerol—inositol 3-phosphatidyltransferase EC 2.7.8.12: CDP-glycerol glycerophosphotransferase EC 2.7.8.13: phospho-N-acetylmuramoyl-pentapeptide-transferase EC 2.7.8.14: CDP-ribitol ribitolphosphotransferase EC 2.7.8.15: UDP-N-acetylglucosamine—dolichyl-phosphate N-acetylglucosaminephosphotransferase EC 2.7.8.16: deleted, now included with EC 2.7.8.2 diacylglycerol cholinephosphotransferase EC 2.7.8.17: UDP-N-acetylglucosamine—lysosomal-enzyme N-acetylglucosaminephosphotransferase EC 2.7.8.18: UDP-galactose—UDP-N-acetylglucosamine galactose phosphotransferase EC 2.7.8.19: UDP-glucose—glycoprotein glucose phosphotransferase EC 2.7.8.20: phosphatidylglycerol—membrane-oligosaccharide glycerophosphotransferase EC 2.7.8.21: membrane-oligosaccharide glycerophosphotransferase EC 2.7.8.22: 1-alkenyl-2-acylglycerol choline phosphotransferase EC 2.7.8.23: carboxyvinyl-carboxyphosphonate phosphorylmutase EC 2.7.8.24: CDP-diacylglycerol—choline O-phosphatidyltransferase EC 2.7.8.25: Now EC 2.4.2.52, triphosphoribosyl-dephospho-CoA synthase EC 2.7.8.26: adenosylcobinamide-GDP ribazoletransferase EC 2.7.8.27: sphingomyelin synthase EC 2.7.8.28: 2-phospho-L-lactate transferase EC 2.7.8.29: L-serine-phosphatidylethanolamine phosphatidyltransferase EC 2.7.8.30: Now EC 2.4.2.53, undecaprenyl-phosphate 4-deoxy-4-formamido-L-arabinose transferase EC 2.7.8.31: undecaprenyl-phosphate glucose phosphotransferase EC 2.7.8.32: 3-O-α-D-mannopyranosyl-α-D-mannopyranose xylosylphosphotransferase EC 2.7.8.33: UDP-N-acetylglucosamine—undecaprenyl-phosphate N-acetylglucosaminephosphotransferase EC 2.7.8.34: CDP-L-myo-inositol myo-inositolphosphotransferase EC 2.7.8.35: UDP-N-acetylglucosamine—decaprenyl-phosphate N-acetylglucosaminephosphotransferase EC 2.7.8.36: undecaprenyl phosphate N,N′-diacetylbacillosamine 1-phosphate transferase EC 2.7.8.37: α-D-ribose 1-methylphosphonate 5-triphosphate synthase EC 2.7.8.38: archaetidylserine synthase EC 2.7.8.39: archaetidylinositol phosphate synthase EC 2.7.8.40: UDP-N-acetylgalactosamine-undecaprenyl-phosphate N-acetylgalactosaminephosphotransferase EC 2.7.8.41: cardiolipin synthase (CMP-forming) EC 2.7.8.42: Kdo2-lipid A phosphoethanolamine 7′′-transferase EC 2.7.8.43: lipid A phosphoethanolamine transferase EC 2.7.8.44: teichoic acid glycerol-phosphate primase EC 2.7.8.45: teichoic acid glycerol-phosphate transferase EC 2.7.8.46: teichoic acid ribitol-phosphate primase EC 2.7.8.47: teichoic acid ribitol-phosphate polymerase
=== CaMK2B === CaMK2B has an autophosphorylation site at Thr287. It functions as a targeting or docking module. Reverse transcription-polymerase chain reaction and sequencing analysis identified at least five alternative splicing variants of beta CaMKII (beta, beta6, betae, beta'e, and beta7) in brain and two of them (beta6 and beta7) were first detected in any species.
=== Biology and medicine === Cerebral palsy Certified Prosthetist, an American medical qualification Ceruloplasmin, an enzyme encoded by the CP gene Congenital prosopagnosia, a type of inability to recognize faces Chronic pancreatitis
Sources: en.wikipedia.org
=== Leak === On September 19, the Half-Life 2 source code was obtained by a German hacker, Axel Gembe, who had infiltrated Valve's internal network months earlier. According to Gembe, he shared it with another person, who leaked the code online in early October. Fans soon compiled a playable version of Half-Life 2, revealing how unfinished it was. The leaks damaged morale at Valve and slowed development. Fans also provided Valve with the details of people involved in the leaks. In March 2004, Gembe contacted Newell, saying he was a fan and had not acted maliciously. Newell worked with the FBI to invite Gembe to a fake job interview, planning to have him arrested in the United States; however, police arrested him in Germany. In November 2006, Gembe was sentenced to two years' probation. Valve implemented new policies to protect against leaks, such as requiring journalists to attend their office to play it before release.
Valproate (valproic acid, VPA, sodium valproate, or valproate semisodium) is a medication primarily used to treat epilepsy and as a mood stabilizer in the treatment of bipolar disorder. It is useful for the prevention of seizures in those with absence seizures, partial seizures, and generalized seizures. It can be given intravenously or by mouth, and the tablet forms exist in both long- and short-acting formulations. Common side effects of valproate include nausea, vomiting, somnolence, and dry mouth. Serious side effects can include liver failure, and regular monitoring of liver function tests is therefore recommended. Other serious risks include pancreatitis and an increased suicide risk. Valproate is known to cause serious abnormalities or birth defects in the fetus if taken during pregnancy, and is contra-indicated for women of childbearing age unless the drug is essential to their medical condition and the person is also prescribed a contraceptive. Reproductive warnings have also been issued for men using the drug. Valproate is restricted in the United Kingdom for both women and men under age 55 due to teratogenicity in pregnant women and fertility problems in men. It is also restricted in the European Union. The United States Food and Drug Administration has indicated a black box warning given the frequency and severity of the side effects and teratogenicity. Additionally, there is also a black box warning due to risk of hepatotoxicity and pancreatitis. Valproate has been in use in Japan for the prophylaxis of migraine since 2011.
While roughly 400 public buildings in Ontario contain RAAC, the Science Centre is currently the only one in the province closed due to these concerns. The Ford government expedited its plan to relocate the Science Centre to the waterfront, targeting a 2028 opening, with a temporary location slated for January 2026. This drew further criticism, including from Moriyama Teshima Architects, the firm founded by the Science Centre's original architect. The architects offered to do pro bono design consulting services for the Government of Ontario to support immediate repairs to the roof, and called for other organizations to join the effort to facilitate repairs. Private donors, including Geoffrey Hinton, offered up to $1 million to fund repairs for the existing facility, but the province did not respond to these offers. By October 31, 2024, most of the exhibits had been moved to storage facilities in northern Toronto and Guelph, while the animals and plants had been transferred to the Toronto Zoo and The Village at Black Creek. Temporary pop-up exhibits have since opened at Sherway Gardens and Toronto's Harbourfront Centre.
Sources: en.wikipedia.org
=== Scientific === In laboratories, a slurry of dry ice in an organic solvent is a useful freezing mixture for cold chemical reactions and for condensing solvents in rotary evaporators. Dry ice and acetone forms a cold bath of −78 °C (−108 °F; 195 K), which can be used for instance to prevent thermal runaway in a Swern oxidation. The process of altering cloud precipitation can be done with the use of dry ice. It was widely used in experiments in the US in the 1950s and early 1960s before it was replaced by silver iodide. Dry ice has the advantage of being relatively cheap and completely non-toxic. Its main drawback is the need to be delivered directly into the supercooled region of clouds being seeded.
=== Vitamin B12 === Spirulina contains no vitamin B12 naturally, and spirulina supplements are not considered a reliable source of vitamin B12, as they contain predominantly pseudovitamin B12 (Coα-[α-(7-adenyl)]-Coβ-cyanocobamide), which is biologically inactive in humans. In a 2009 position paper on vegetarian diets, the American Dietetic Association stated that spirulina is not a reliable source of active vitamin B12. The medical literature similarly advises that spirulina is unsuitable as a source of B12.
Physicians have been advised to help patients interested in looksmaxxing to distinguish between safe beauty practices and harmful practices, suggesting to patients to only conduct looksmaxxing practices when done in a medically viable manner. Clavicular's system of rating looksmaxxing that he promotes in interviews and on social media is the PSL scale, which gives men a numerical rating then sorts men into three tiers: "subhuman", "normie", and "Chad". In her New Yorker criticism, journalist Becca Rothfeld explains, "The moral objections to looksmaxxing are numerous, severe, and obvious. A system that designates any person as 'subhuman' is beneath contempt, and that's to say nothing of the racial slurs to which looksmaxxing stalwarts help themselves regularly." She also cites a recent interview in which Clavicular "approvingly notes that Brad Pitt 'mogs' Mother Teresa". While its encouragement for men to care about their health and fitness can be seen as a positive, looksmaxxing overall is seen as demoralising to men, especially the young. A study published in the National Library of Medicine argues that looksmaxxing promotes a hegemonic masculine gaze on male bodies. Hegemonic masculinity is a social concept developed by R. W. Connell that defines the ideal form of dominant and physically attractive male bodies, legitimizes sexism, and reinforces patriarchy. The study's findings support its argument, and proves that the looksmaxxing community revolves around male supremacy and hegemonic masculinity.
Sources: en.wikipedia.org
It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.
It binds the growth hormone-releasing hormone receptor on anterior pituitary cells. Activation of that receptor promotes synthesis and release of growth hormone. The effect propagates through the growth hormone and insulin-like growth factor 1 axis.
Native GHRH is cleared quickly by peptidases, which limits how long it can stimulate its receptor. The added group hinders one of the primary cleavage enzymes. The practical consequence is a longer period of receptor activity per dose.
The principal difference is a chemical cap on the N-terminal tyrosine that prevents rapid enzymatic cleavage. Native GHRH is degraded within minutes in plasma, whereas the modified peptide persists considerably longer. The amino acid backbone otherwise mirrors the natural hormone.